GlassScriptPhysician profile
Mallu C Reddy
NPI 1942278221
$17,839.26
in general payments reported to CMS, 2019-2025
60 companies · $2,682 in 2025
The $2,682 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,081 · 2020: $1,606 · 2021: $1,984 · 2022: $3,409 · 2023: $1,935 · 2024: $4,143 · 2025: $2,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,753 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $1,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,752.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $1,006.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $2,095.01 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $1,787.06 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,302.46 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $1,216.32 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $1,209.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $889.03 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $656.17 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $615.03 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Sk Life Science, INC. | $598.24 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $576.23 | 2019-2022 | |
| Medtronic, INC. | $568.00 | 2025 | Minimed 780g |
| Ucb, INC. | $563.28 | 2020-2023 | Briviact, Nayzilam |
| Amgen INC. | $562.60 | 2019-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $474.45 | 2021-2025 | |
| Glaxosmithkline, LLC. | $449.04 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $426.11 | 2019-2022 | |
| Amarin Pharma, INC. | $357.44 | 2019-2022 | |
| Eisai INC. | $304.16 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $292.32 | 2023-2025 | Gemtesa, Aptiom |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.83 | 2020-2025 | Jardiance |
| Vanda Pharmaceuticals INC. | $272.10 | 2022-2023 | Hetlioz, Fanapt |
| Abbvie INC. | $248.87 | 2022-2024 | |
| Esperion Therapeutics, INC. | $205.19 | 2020-2023 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.60 | 2021-2025 | Xifaxan |
| Abbott Laboratories | $179.83 | 2021-2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $168.22 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $146.39 | 2022-2025 | Jynarque, Rexulti |
| Corium, LLC | $132.49 | 2022-2023 | Adlarity |
| Dexcom, INC. | $118.75 | 2022-2025 | Dexcom G6 Transmitter |
| Biogen, INC. | $92.29 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $86.20 | 2019-2022 | |
| Shield Therapeutics INC | $71.74 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $68.25 | 2021 | |
| Mannkind Corporation | $56.53 | 2020-2021 | |
| Ardelyx, INC. | $54.70 | 2024-2025 | Ibsrela |
| Biohaven Pharmaceutical Holding Company LTD. | $51.29 | 2022 | |
| Astellas Pharma US INC | $44.03 | 2019-2025 | Veozah |
| Hologic Sales and Service, LLC | $40.32 | 2023-2024 | Aptima, Thinprep 2000 Processor, Affirm Prone Biopsy System |
| Xeris Pharmaceuticals, INC. | $39.47 | 2022-2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $35.68 | 2025 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $32.41 | 2020 | |
| Averitas Pharma INC. | $31.43 | 2024 | Qutenza |
| Optos, INC. | $28.71 | 2020-2021 | |
| Urovant Sciences INC | $23.61 | 2022 | |
| Kyowa Kirin, INC. | $22.54 | 2024 | Nourianz |
| Scilex Pharmaceuticals INC. | $20.62 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $19.80 | 2022 | |
| Amryt Pharma Holdings LTD | $19.09 | 2022 | |
| Linus Health, INC. | $18.50 | 2024 | Core Cognitive Evaluation |
| Lundbeck LLC | $17.47 | 2025 | Rexulti |
| Amphastar Pharmaceuticals, INC. | $17.04 | 2024 | |
| Gilead Sciences, INC. | $15.40 | 2025 | |
| Bard Peripheral Vascular, INC. | $15.09 | 2022 | |
| Neurelis, INC. | $14.43 | 2022 | |
| Venclose INC. | $9.31 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,273.35 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallu Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.